Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AAA, accredited, alkylating, allogeneic, ambient, amylin, annuity, antibody, antidiabetic, apprised, assist, assistance, ataxia, attenuated, automatically, Bach, barrier, biased, blocker, brand, BTB, cadisegliatin, calendar, Carcinogenicity, cardio, certified, Clawback, CNC, cognizant, competitor, concurrence, concurrent, Concurrently, confusion, construed, counsel, Cowen, creditworthy, cured, CUSIP, deducting, degeneration, Diasome, dipeptidyl, dissuade, distance, district, documentary, domain, Donislecel, donor, dopaminergic, draft, durability, erythroid, evidentiary, exert, extracellular, Fatigue, footnote, formulation, forum, fractional, Friedreich, glycosylated, greatly, hand, HDV, hemoglobin, homology, hope, immunosuppressive, inadvertent, inadvertently, ineffective, instruction, inventor, islet, ISO, Keith, kinase, KO, Lantidra, lax, legitimate, lifespan, lifetime, ligand, lipopolysaccharide, lispro, mavodelpar, mice, MPTP, nearest, neuroprotection, neuroprotective, neurotoxicity, ninety, nocturnal, noncash, nonemployee, nonobese, nonspecific, nuclear, opposition, opt, output, paradigm, Parkinson, passed, PD, PGR, pharmacological, playbook, poor, pose, posture, prejudiced, procedural, proportionate, rarely, ratification, ratio, recovery, recurrent, reexamination, region, reinterpreted, Repurchase, resultantly, retroactively, revocation, revoke, revoked, rounded, score, secondary, Secretary, shortly, sixteen, SOC, somatostatin, split, STRIDE, Supreme, Symlin, systolic, TD, Teplizumab, threatened, TID, titled, top, traditional, transparency, trend, Tzield, Unified, unpatented, unregistered, upheld, uptake, Vesicle, walk, walked, weaken, weakening, weekly, withdrawn, wrongfully, Zucara
Removed:
accretion, AEs, aggregated, Aid, Alzheimer, AMT, arithmetic, back, bore, borrowed, Cap, computing, consumption, correction, covenant, covenanted, directing, discernable, discretion, encumber, expensing, extinguished, feedback, floating, hedging, incurrence, intensive, Interbank, investee, IRC, lesser, LIBOR, likewise, liquidate, London, lowest, newly, nominating, pair, pandemic, penalty, percent, permitting, pledge, pledged, preceding, progression, recoverability, refund, registering, Regular, remote, repaid, repayment, resume, scheduled, STEADFAST, traded, whatsoever
Financial report summary
?Competition
Pfizer • AMGEN • Astrazeneca • Sanofi • Oramed Pharmaceuticals • Diasome PharmaceuticalsRisks
- We have incurred significant losses since inception and anticipate that we will incur continued losses for the foreseeable future. We may never achieve or maintain profitability.
- Currently, we have no products approved for commercial sale, and to date we have not generated any revenue from product sales. As a result, our ability to generate revenue from products, curtail our losses and reach profitability is unproven, and we may never generate substantial product revenue.
- We will need additional capital to complete the development and commercialization of cadisegliatin (TTP399) and our other drug candidate. If we are unable to raise sufficient capital for these purposes, we would be forced to delay, reduce or eliminate our product development programs.
- Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or drug candidates.
- We have a limited operating history, and we expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance.
- Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any drug candidate we advance through various stages of clinical trials or development may not have favorable results in later stages of clinical trials or development or receive regulatory approval.
- We cannot be certain that any of our drug candidates will receive regulatory approval, and without regulatory approval we will not be able to market our drug candidates and generate revenue from products. Any delay in the regulatory review or approval of our drug candidates will materially and adversely affect our business.
- Changes in law could have a negative impact on the approval of our drug candidates.
- Delays in the commencement, enrollment and completion of our clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for our drug candidates.
- We have never submitted an NDA before and may be unable to do so for cadisegliatin (TTP399) and our other drug candidates we are developing.
- Our drug candidates may cause serious adverse events or undesirable side effects which may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.
- If any of our drug candidates for which we receive regulatory approval do not achieve broad market acceptance, the revenues that are generated from their sales will be limited.
- If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our drug candidates, we may not be successful in commercializing our drug candidates if and when they are approved.
- Even if our drug candidates receive regulatory approval, we will still be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense, and we may still face future development and regulatory difficulties.
- We expect that our existing and future drug candidates will face competition, and most of our competitors have significantly greater resources than we do.
- Current and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of our other drug candidates and affect the prices we, or they, may obtain.
- Our current and future relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable healthcare laws and regulations.
- If we try to obtain approval to commercialize any products outside the United States, many of the same risks that apply to obtaining approvals in the United States will likely apply to such a process, and even if we obtain approval to commercialize any such products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.
- We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize our drug candidates successfully, if at all.
- We rely on third parties to conduct, supervise and monitor certain of our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.
- We do not have multiple sources of supply for the components used in cadisegliatin (TTP399) and our other drug candidates. If we were to lose a supplier, it could have a material adverse effect on our ability to complete the development of cadisegliatin or our other drug candidates. If we obtain regulatory approval for cadisegliatin or our other drug candidates, we would need to expand the supply of their components in order to commercialize them.
- We intend to rely on third-party manufacturers to produce our drug candidates. If we experience problems with any of these suppliers, the manufacturing of our drug candidates or products could be delayed.
- Our success depends on our ability to protect our intellectual property and our proprietary technologies. If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our commercial success may be adversely affected.
- If we are unable to prevent disclosure of our trade secrets or other confidential information to third parties, our competitive position may be impaired.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- Changes to the patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products candidates and future products.
- If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.
- If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation could harm our business.
- We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
- Our patent rights may prove to be an inadequate barrier to competition.
- We may not be able to enforce all of our intellectual property rights throughout the world.
- Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
- If we do not obtain patent term extensions for our drug candidates, the length of our patent exclusivity will be shorter which may harm our business materially.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
- If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected, harming our business and competitive position.
- We may be subject to claims that we or our employees, independent contractors, or consultants have wrongfully used or disclosed alleged confidential information or trade secrets.
- We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees, independent contractors, or consultants have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.
- The patent protection and patent prosecution for some of our product candidates may be dependent on third parties.
- We may need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth.
- We may not be able to manage our business effectively if we are unable to attract and retain key personnel.
- Our employees, independent contractors, principal investigators, CROs, consultants and collaborators may engage in misconduct or other improper activities, including noncompliance with legal, compliance or regulatory standards and requirements.
- We may use our financial and human resources to pursue a particular research program or drug candidate and fail to capitalize on programs or drug candidates that may be more profitable or for which there is a greater likelihood of success.
- We may be subject to litigation or government investigations for a variety of claims, which could adversely affect our operating results, harm our reputation or otherwise negatively impact our business.
- If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any future products we develop.
- Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities.
- The market for our proposed products is rapidly changing and competitive, and new drugs and new treatments that may be developed by others could impair our ability to maintain and grow our businesses and remain competitive.
- Our business and operations would suffer in the event of computer system failures, cyber-attacks or a deficiency in our cyber-security.
- If we are unable to maintain listing of our Class A common stock on the Nasdaq Capital Market or another national stock exchange, it may be more difficult for our stockholders to sell their Class A common stock.
- Affiliates of MacAndrews & Forbes Incorporated (together with its affiliates “MacAndrews”) has substantial influence over our business, and their interests may differ from our interests or those of our other stockholders.
- Our directors who have relationships with MacAndrews and the investors that participated in the Private Placement (the “Private Placement Investors”) may have conflicts of interest with respect to matters involving our company.
- We do not anticipate paying cash dividends on our Class A common stock, and accordingly, stockholders must rely on stock appreciation for any return on their investment.
- Our share price may be volatile, which could subject us to securities class action litigation and result in substantial losses for our stockholders.
- The trading market for our Class A common stock will be influenced by the research and reports that equity research analysts publish about us and our business.
- A substantial portion of our total outstanding shares may be sold into the market at any time. This could cause the market price of our Class A common stock to drop significantly, even if our business is doing well.
- Future sales and issuances of our Class A common stock or rights to purchase Class A common stock, including pursuant to our equity incentive plans or the exercise of outstanding warrants, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
- We incur significant costs and devote substantial management time as a result of operating as a public company and additional resources would be required if we lose our “smaller reporting company” and “non-accelerated filer” status.
- Provisions in our charter and bylaws and investor agreements, and provisions of Delaware law may delay or prevent our acquisition by a third party, which might diminish the value of our common stock.
- We will be required to pay M&F TTP Holdings Two LLC (“M&F”) for certain tax benefits we may claim. In certain circumstances, payments under the Tax Receivable Agreement may be accelerated and/or significantly exceed the actual tax benefits we realize.
- The only asset of the Company is its interest in vTv LLC, and accordingly it will depend on distributions from vTv LLC to pay taxes and expenses, including payments under the Tax Receivable Agreement. vTv LLC’s ability to make such distributions may be subject to various limitations and restrictions.
- Our organizational structure confers certain benefits upon M&F and certain of its successors and assigns that will not benefit Class A common stockholders to the same extent as it will benefit M&F.